Investigational New Drug CDMO Market Size, Share & Trends Analysis Report By Product (Small Molecule, Large Molecule), By Service (Pharmaceutical Companies, Biotech Companies, Others), By End-User, By Region, And By Segment Forecasts, 2025-2034

Chapter 1. Methodology and Scope 1.1. Research Methodology 1.2. Research Scope & Assumptions Chapter 2. Executive Summary Chapter 3. Global Investigational New Drug CDMO Market Snapshot Chapter 4. Global Investigational New Drug CDMO Market Variables, Trends & Scope 4.1. Market Segmentation & Scope 4.2. Drivers 4.3. Challenges 4.4. Trends 4.5. Investment and Funding Analysis 4.6. Industry Analysis – Porter's Five Forces Analysis 4.7. Competitive Landscape & Market Share Analysis 4.8. Impact of Covid-19 Analysis Chapter 5. Market Segmentation 1: by Product Type Estimates & Trend Analysis 5.1. by Product Type & Market Share, 2024 & 2034 5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Product Type: 5.2.1. Percutaneous Endovascular Aneurysm Repair (EVAR) 5.2.2. Fenestrated EVAR 5.2.3. Aortic Stents Biodegradable Stents 5.2.4. Self- Expanding Nitinol Stents 5.2.5. Thoracic Aortic Aneurysm Grafts 5.2.6. Other Devices Chapter 6. Market Segmentation 2: by Service Estimates & Trend Analysis 6.1. by Service & Market Share, 2024 & 2034 6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Service: 6.2.1. Contract Development 6.2.1.1. Small Molecule 6.2.1.1.1. Bioanalysis and DMPK studies 6.2.1.1.2. Toxicology Testing 6.2.1.1.3. Pathology and safety pharmacology studies 6.2.1.1.4. Drug substance synthetic route development 6.2.1.1.5. Drug substance process development 6.2.1.1.6. Form selection crystallization process development 6.2.1.1.7. Scale-up of drug substance 6.2.1.1.8. Preformulation 6.2.1.1.9. Preclinical formulation selection 6.2.1.1.10. First in Man Formulation/Process Development 6.2.1.1.11. Analytical method development/validation 6.2.1.1.12. Release testing of drug substance and drug product 6.2.1.1.13. Work up Purification Steps 6.2.1.1.14. Telescoping & Process Refining 6.2.1.1.15. Initial Optimization 6.2.1.1.16. Formal stability of drug substance and drug product 6.2.1.2. Large Molecule 6.2.1.2.1. Cell Line development 6.2.1.2.2. Process Development 6.2.1.2.2.1. Upstream 6.2.1.2.2.1.1. Microbial 6.2.1.2.2.1.2. Mammalian 6.2.1.2.2.1.3. Others 6.2.1.2.2.2. Downstream 6.2.1.2.2.2.1. MABs 6.2.1.2.2.2.2. Recombinant proteins 6.2.1.2.2.2.3. Others 6.2.2. Contract Manufacturing 6.2.2.1. Small Molecule 6.2.2.1.1. Oral Solids 6.2.2.1.2. Liquid and Semi-solids 6.2.2.1.3. Injectables 6.2.2.1.4. Others 6.2.2.2. Large Molecule 6.2.2.2.1. MABs 6.2.2.2.2. Recombinant proteins 6.2.2.2.3. Others Chapter 7. Market Segmentation 3: by End-user Estimates & Trend Analysis 7.1. by End-user & Market Share, 2024 & 2034 7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by End-user: 7.2.1. Pharmaceutical Companies 7.2.2. Biotech Companies 7.2.3. Others (Government, Research Institutes, Academic Institutes, Etc.) Chapter 8. Investigational New Drug CDMO Market Segmentation 4: Regional Estimates & Trend Analysis 8.1. North America 8.1.1. North America Investigational New Drug CDMO Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2021-2034 8.1.2. North America Investigational New Drug CDMO Market Revenue (US$ Million) Estimates and Forecasts by Service, 2021-2034 8.1.3. North America Investigational New Drug CDMO Market revenue (US$ Million) by End-user, 2021-2034 8.1.4. North America Investigational New Drug CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034 8.2. Europe 8.2.1. Europe Investigational New Drug CDMO Market revenue (US$ Million) by Product Type, 2021-2034 8.2.2. Europe Investigational New Drug CDMO Market revenue (US$ Million) by Service, 2021-2034 8.2.3. Europe Investigational New Drug CDMO Market revenue (US$ Million) by End-user, 2021-2034 8.2.4. Europe Investigational New Drug CDMO Market revenue (US$ Million) by country, 2021-2034 8.3. Asia Pacific 8.3.1. Asia Pacific Investigational New Drug CDMO Market revenue (US$ Million) by Product Type, 2021-2034 8.3.2. Asia Pacific Investigational New Drug CDMO Market revenue (US$ Million) by Service, 2021-2034 8.3.3. Asia-Pacific Investigational New Drug CDMO Market revenue (US$ Million) by End-user, 2021-2034 8.3.4. Asia Pacific Investigational New Drug CDMO Market revenue (US$ Million) by country, 2021-2034 8.4. Latin America 8.4.1. Latin America Investigational New Drug CDMO Market revenue (US$ Million) by Product Type, 2021-2034 8.4.2. Latin America Investigational New Drug CDMO Market revenue (US$ Million) by Service, 2021-2034 8.4.3. Latin America Investigational New Drug CDMO Market revenue (US$ Million) by End-user, 2021-2034 8.4.4. Latin America Investigational New Drug CDMO Market revenue (US$ Million) by country, 2021-2034 8.5. Middle East & Africa 8.5.1. Middle East & Africa Investigational New Drug CDMO Market revenue (US$ Million) by Product Type, 2021-2034 8.5.2. Middle East & Africa Investigational New Drug CDMO Market revenue (US$ Million) by Service, 2021-2034 8.5.3. Middle East & Africa Investigational New Drug CDMO Market revenue (US$ Million) by End-user, 2021-2034 8.5.4. Middle East & Africa Investigational New Drug CDMO Market revenue (US$ Million) by country, 2021-2034 Chapter 9. Competitive Landscape 9.1. Major Mergers and Acquisitions/Strategic Alliances 9.2. Company Profiles 9.2.1. Covance Inc. 9.2.2. Charles River Laboratories Inc. 9.2.3. Cambrex Corporation 9.2.4. IQVIA Holdings Inc. 9.2.5. Syneos Health 9.2.6. Lonza 9.2.7. Catalent 9.2.8. Recipharm AB 9.2.9. Siegfried Holding AG 9.2.10. Thermo Fisher Scientific Inc. 9.2.11. Other Prominent Players